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Purpose: A considerable body of non clinical evidence has accumulated to support peroxisomal
proliferator-activated receptor gamma agonists as candidate anti-inflammatory drugs in
asthma. We utilized rosiglitazone as a tool compound in the inhaled allergen challenge model
of asthma.
Methods: A single centre, double-blind, randomised, placebo controlled, two period cross-
over study. Subjects received rosiglitazone 4 mg and placebo twice daily for 28 days in random
order. On day 28, inhaled allergen challenge was performed 1 hour post-dose. A methacholine
challenge was performed on day 29 and an adenosine monophosphate challenge on day 14.
Exhaled nitric oxide was measured on days 1, 14, 28, 29. Blood was collected pre dose on days
1, 14 and 28 and analysed for markers associated with PPAR activity and systemic markers of
inflammation.
Results: The late asthmatic reaction (LAR) change from post saline FEV1 from 4e10 hrs post
allergen on day 28 was statistically significant for the weighted mean LAR. The difference in
weighted mean was 0.06 L (95% CI 0.01 to 0.11) which equates to a 15% attenuation of the
response during placebo treatment. This was accompanied by trends in other markers of effi-
cacy and anti-inflammatory activity but none were considered major effects.
Discussion: Treatment with a PPARg agonist (rosiglitazone) was associated with a modest (15%)
reduction in the late asthmatic reaction in the allergen challenge model of asthma. Based on223 296159.
rds@gsk.com (D.B. Richards), philippe.j.bareille@GSK.com (P. Bareille), emma.l.lindo@GSK.com
(D. Quinn), stuart.n.farrow@gsk.com (S.N. Farrow).
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Treatment with a PPARg agonist in asthma 669the results of this study, PPARg agonist monotherapy is unlikely to represent a clinically useful
intervention in human asthma.
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Figure 1 Study design.Background
Inhaled glucocorticoids are highly effective and form the
mainstay of asthma preventive therapy. Nevertheless they
are not universally effective and may be associated with
adverse systemic effects, especially at high doses. There
remains substantial unmet need for effective alternative
anti-inflammatory treatments in asthma. The peroxisome
proliferator-activated receptors (PPARs) comprise three
closely related members, PPARa, PPARd and PPARg.
Synthetic ligands for PPARg such as rosiglitazone (a thia-
zolidinedione) have benefits in diabetes mellitus via tran-
scriptional regulation of lipid and glucose metabolism.1,2
PPARg receptors are expressed in a several important
immune cells, which has prompted investigation of their
potential as immune regulators and anti-inflammatories.
The PPARg receptor has been shown to be up-regulated
in asthmatic epithelium,3 and PPARg agonists in vitro have
a range of effects on inflammatory cells including macro-
phage function, inhibition of tumour necrosis factor
production, inhibition of T-cell proliferation and cytokine
production. These and other observations have prompted
investigation of PPARg agonist effects in various models of
allergic asthma and airway inflammation. Positive results in
these studies have led to suggestions that PPARg agonists
might have utility for the treatment of human allergic
asthma and chronic obstructive airways disease.4 Most
recently a study in smoking asthmatics showed an
improvement in FEV1 after 4 weeks rosiglitazone treatment
compared with beclometasone treatment.5
Rosiglitazone (GSK) is licensed for the treatment of type
II diabetes mellitus and we utilized it as a tool compound to
explore the potential for an anti-inflammatory effect in
mild asthmatics using the well-established inhaled allergen
challenge model.
We performed a randomised double blind, placebo
controlled, 2 period crossover study in steroid naı¨ve asthma
patients comparing the effects of rosiglitazone and placebo
on airway hyper-reactivity and markers of inflammation.
Methods
Subjects
Thirty four steroid naı¨ve patients with physician diagnosed
asthma for at least 6 months were recruited. Subjects were
required to be aged 18 to 55 years and non-smokers for at
least 6 months with less than a 10 pack year history. At
screening patients were required to have an FEV1> 70%
predicted, have a positive skin test to either house dust
mite, grass pollen or cat allergen, and to demonstrate both
an early and late asthmatic reaction to one of these aller-
gens when inhaled. The early asthmatic response (EAR)included a fall of 20% from the post saline value on at
least one occasion between 10 and 30 minutes after the
final concentration of allergen. The late asthmatic response
(LAR) included a fall of 15% from the post saline value on
at least three occasions, two of which were consecutive,
between 4 and 10 h after the final concentration of
allergen. They were also required to have an adenosine
monophosphate (AMP) and methacholine PC20 (provocative
concentration causing a 20% fall in FEV1) less than 100 mg/
ml and 8 mg/ml (or PD20 3.2 mg) respectively. All
patients provided written informed consent. The study was
approved by the local research ethics committee.
Study design
This was a single centre, double-blind, randomised,
placebo controlled, two period cross-over study. Fig. 1
shows the study design. Eligible subjects received rosigli-
tazone 4 mg and matched placebo twice daily for 28 days in
random order. During each treatment period subjects were
instructed to take the study medication at the same time of
day. The washout period was 14e28 days between treat-
ment periods to allow sufficient time between allergen
challenges and flexibility of study visit scheduling. Subjects
had observed dosing on days 1, 14, 28 and 29 and were
required to refrain from short-acting beta agonist use for 8
hrs prior to each clinic visit. Heart rate, blood pressure and
forced expiratory volume in 1 second (FEV1), were
measured on days 1, 14, 28, and 29. Pedal oedema was
measured on days 1, 14, and 28. On day 14, subjects
underwent an AMP challenge within 1e3 hours post-dose.
On day 28, an inhaled allergen challenge was performed
1 hour post-dose. A methacholine challenge was then per-
formed on day 29 at 23 hours post allergen challenge
(24 hours post dose). Details of the bronchial challenges are
provided in the online data supplement. Exhaled nitric
oxide (FENO) was measured using the NIOX analyser at
a flow of 50 mL/s. Measurements were taken pre dose on
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Figure 2 Flow of patients through study, showing number
screened, randomised, withdrawn, and completed. Excluded
patients did not fulfil the inclusion criteria (majority did not
demonstrate a late asthmatic reaction).
670 D.B. Richards et al.days 1, 14, 28, pre challenge on day 29, and post challenge
on days 14 and 29. Blood was collected pre dose for
biomarker analysis on days 1, 14 and 28; it was analysed for
markers of PPAR-g activity (specifically adiponectin) and
for systemic markers of inflammation. Sputum was
collected pre dose on Day 1, and post challenge and after
exhaled nitric oxide measurement on Days 14 and 29.
Adverse events and beta agonist use were monitored
throughout the study with the aid of diary cards.
Statistical analysis
Bronchial challenge endpoints were analysed using mixed
effect models with treatment and period fitted as fixed
effects and subject fitted as a random effect. Subject’s
overall mean baseline and period baseline were fitted as
covariates (fixed effects). Confidence intervals (CI) where
quoted are two-sided 95% CIs. Statistical significance at the
5% level is concluded where the 95% confidence interval for
the treatment difference excludes 0 for the challenge
endpoints and excludes 1 for the exhaled NO endpoints.
Further details regarding the statistical methods are
described in the online data supplement.
Results
Thirty four subjects (see Table 1 for demography) were
planned and randomised of whom thirty two completed the
study. One subject was withdrawn following Period 1
(rosiglitazone) on Day 50 due to a protocol violation (posi-
tive drugs of abuse test). One subject was withdrawn prior
to completing Period 1 (rosiglitazone) on Day 10 due to an
adverse event of tachycardia associated with a feeling of
nervousness. The numbers of patients screened, excluded,
randomised and withdrawn are summarised in Fig. 2.
Study medications were well tolerated. The most
frequently reported adverse event was headache (reported
by 12 subjects (38%) on placebo, 14 (41%) on rosiglitazone).
Five adverse events (AEs) were rated as severe intensity; no
events fulfilling the criteria for a Serious Adverse Event
were reported. Following rosiglitazone, the AEs judged to
be of severe intensity were one episode of sinusitis, two
episodes of muscle spasm, and one episode of influenza.
Following placebo, one subject reported a severe AE of
sinusitis, which resolved and was judged to be unrelated to
treatment. This subject had also reported severe sinusitisTable 1 Subject demography.
Age, yr 30.5 (20e46)
Duration of asthma, yrs 21.94 (8e39)
Sex 21 male/13 female
FEV1, L 3.45 (1.93e5.69)
FEV1, % predicted 89.3 (71.0e123.4)
FENO, ppb 69.3 (16.1e216.1)
Allergens used for
bronchial challenge
20 dust mite, 7 cat hair,
5 grass mix
Definition of abbreviations: FENOZ exhaled breath nitric oxide.
Data were collected before the first treatment period. Values
represent mean (range), except for FENO data, which are pre-
sented as geometric mean (range).following rosiglitazone. No treatment related trends were
observed in safety laboratory parameters, blood pressure,
ECG parameters, beta agonist reliever use and pre-dose
FEV1 values. Most pedal oedema ratings were grade
0 (<1 mm) throughout the study. One subject had an
oedema rating of grade 2 (3 to 5 mm) at Day 28 on placebo
and one subject had an oedema rating of grade 2 at Day 28
on rosiglitazone. None of the cases of peripheral oedema
were considered clinically significant.
Allergen challenge
Early asthmatic response (EAR)
The EAR FEV1 change from post saline baseline on day 28
was similar during treatment with roglitazone and placebo
(Fig. 3). There was no significant difference for either the
minimum FEV1 or weighted mean FEV1 change from base-
line endpoints (Table 2).
Late asthmatic response (LAR)
The change from post saline baseline FEV1 from 4e10 hrs
post allergen on day 28 was not statistically significant for
the minimum LAR during treatment with rosiglitazone
compared with placebo but was statistically significant for
the weighted mean LAR (Fig. 3; Table 2). The difference in
weighted mean was 0.06 L (95% CI 0.01 to 0.11) which
equates to a 15% attenuation of the response during
placebo treatment.
Methacholine challenge
The adjusted geometric mean methacholine PC20 (mg/ml)
performed23 hoursafter theallergenchallengewere0.06 (95%
CI 0.05 to 0.08) and 0.07 (95% CI 0.05 to 0.09) after treatment
with rosiglitazone and placebo respectively. There was no
statistically significant difference between the methacholine
reactivity during dosing with rosiglitazone and placebo (mean
doubling dose difference 0.20, 95% CI 0.62 to 0.22).
AMP challenge
During the course of the study a problem emerged with the
supply of AMP challenge agent that made it impossible to
Figure 3 Early and late asthmatic response to inhaled
allergen challenge after 28 days of treatment with either
rosiglitazone or placebo. Adjusted means and 95% confidence
intervals of change in FEV1 compared with post-saline value are
shown.
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data were therefore missing for 12 subjects in each of the
treatment groups owing to this supply problem.
The adjusted geometric mean AMP PC20 (mg/mL) 1e
3hrs post-dose on day 14 were 1.01 (95% CI 0.55 to 1.89) and
1.49 (95% CI 0.79 to 2.80) after treatment with rosiglitazone
and placebo respectively. There was no statistically
significant difference between the AMP reactivity during
dosing with rosiglitazone and placebo (mean doubling dose
difference 0.55, 95% CI 1.59 to 0.48).
Exhaled NO
Geometric mean and 95% confidence intervals for pre-dose
FENO concentrations on days 1, 14, and 28 are shown in
Table 3. Measurements were also made pre-challenge on
day 29 (24 hours post allergen challenge) and after the
challenges on days 14 (AMP) and 29 (methacholine); these
data are summarised in the supplement (online data
supplement Table E1). FENO (pre dose) in the rosiglitazone
group was reduced on average by 16% from baseline on Day
14 and by 24% on Day 28. In the placebo group, FENO was
reduced on average by 5% from baseline on Day 14 and by
12% on Day 28. There was statistical evidence of a differ-
ence in pre-dose FENO between the rosiglitazone andTable 2 Early and Late asthmatic FEV1 responses.
Absolute Change from
Baseline Endpoint (L)
Adjusted Mean (95% CI)
Rosiglitazone (NZ 34) Placebo (NZ
Early Asthmatic Response (EAR)
Minimum 1.37 (1.54, 1.19) 1.30 (1.48
Weighted Mean 0.37 (0.48, 0.26) 0.34 (0.45
Late Asthmatic Response (LAR)
Minimum 0.84 (0.93, 0.74) 0.90 (1.00
Weighted Mean 0.32 (0.37, 0.27) 0.38 (0.43
a A 95% CI for the treatment difference excluding 0 indicates statisplacebo treatment groups on days 14 and 28. On average,
pre-dose FENO was reduced by 12% (95% CI 1.3 to 22%
reduction) on Day 14 and 14% (95% CI 1.5 to 25% reduction)
on Day 28 following administration of rosiglitazone
compared with placebo.
Biomarkers
Adiponectin was measured as a pharmacodynamic measure
of PPARg activity (and hence also of compliance). There
was a substantial increase in the average blood concen-
tration of adiponectin (7.1 mg/L on Day 1 to 17.2 mg/L on
Day 28), as expected after treatment with rosiglitazone. No
elevation of adiponectin was observed during treatment
with placebo (Day 1 7.5 mg/L; Day 28 6.5 mg/L). There were
no major effects on hsC-reactive protein, interferon (IFN)-
g, interleukin (IL)-4, IL-6, IL-13, matrix metalloproteinase
(MMP)-9 or tumour necrosis factor (TNF)-a, although these
markers tended to be decreased after rosiglitazone (online
data supplement Table E2). There were no trends observed
in the blood differential white cell count measured on days
1, 14, and 28 (online data supplement Table E3).
Sputum differential counts were not analysed and are
not presented owing to the low proportion of samples that
were assessed as viable.
Discussion
PPARg is expressed widely in the lung, in inflammatory,
resident, and structural cells.6 There is a considerable body
of in vitro findings suggesting that PPARg agonists have
anti-inflammatory effects. For example, they reduce TNF,
IL1 and IL6 production in airway epithelial cells, they
reduce eosinophil migration and killing, and reduce IL2, IL5
and IFNg production by T cells.7e9
The in vitro work has been supplemented by work in the
mouse ovalbumin model of airway hyper-responsiveness.
Treatment with a PPARg agonist (ciglitazone) during sensi-
tization, or immediately prior to allergen challenge mark-
edly reduced airway hyper-responsiveness and
inflammatory infiltrate into the lungs.10,11 The doses of
ciglitazone administered are similar to those required in
animal models of diabetes.
In man there is evidence that PPARg is upregulated in
the airway epithelium and smooth muscle cells of those
with asthma.3 Treatment with corticosteroids reducesTreatment Difference (95% CIa)
Rosiglitazone - Placebo
% Attenuation
from Placebo
Response
32)
, 1.12) 0.07 (0.28, 0.15) 5
, 0.23) 0.03 (0.15, 0.09) 9
, 0.80) 0.06 (0.03, 0.16) 7
, 0.32) 0.06 (0.01, 0.11) 15
tical significance at the 5% level.
Table 3 Summary of exhaled nitric oxide data (FENO ppb).
Day Time Placebo (NZ 32) Rosiglitazone (NZ 34)
n Geometric Mean
(95% Confidence Interval)
n Geometric Mean
(95% Confidence Interval)
1 Pre-dose 32 68.23 (54.48, 85.41) 34 74.09 (59.07, 92.92)
14 Pre-dose 30 66.05 (51.18, 85.23) 32 60.34 (47.72, 76.29)
28 Pre-dose 32 64.18 (50.02, 82.33) 33 53.54 (42.62, 67.24)
672 D.B. Richards et al.expression of PPARg, but this observation does not eluci-
date whether this is because PPARg contributes to the
pathophysiology or is simply a marker of inflammatory
process. There are 2 case reports of patients with asthma
reporting reduced wheeze when given a PPARg agonist
(pioglitazone) for the treatment of type II diabetes.12
Taken together these data suggest that PPARg agonists
may have anti-inflammatory effects that are of clinical
benefit in asthma, but evidence in humans is lacking. This
study used rosiglitazone as tool compound to explore this
further in humans.
Rosiglitazone is a high affinity (IC50Z 10 nM) PPARg
agonist.13 It also demonstrates considerable selectivity for
PPARg over other PPAR subtypes (a and d).14
The inhaled allergen challenge model is a well estab-
lished one in which the LAR (4-10 hours post allergen)
appears to correlate with the extent of airway inflamma-
tion and disease activity. Recruitment of activated eosin-
ophils, key cells in the pathogenesis of asthma, underlies
the late bronchoconstrictor response to allergen chal-
lenge.15 The inflammatory response initiated by allergen
challenge extends beyond the changes in FEV1 seen in the
early and late asthmatic response, and can be observed as
increased bronchial hyper-responsiveness for several days
after allergen challenge.16 Inhaled corticosteroids
(including budesonide and fluticasone) reduce the airway
hyper-responsiveness seen after allergen challenge
compared to placebo. The inclusion of a methacholine
assessment on Day 29 increased the sensitivity of the study
to detect an anti-inflammatory effect of treatment with
a PPARg agonist.
AMP is an indirect stimulus of bronchoconstriction,
although its precise mechanism of action is unknown. It is
best validated in terms of the action of corticosteroids.17,18
This challenge was included on day 14 as a secondary
endpoint because studies of inflammatory biomarkers have
shown a statistically significant effect of treatment with
rosiglitazone by Day 14 (the effect is maximal by Day 28
when the allergen challenge (primary endpoint) was
assessed).19
Treatment with PPARg agonists is associated with a rise
in plasma adiponectin and this is a useful pharmacodynamic
marker. Treatment with rosiglitazone 4 mg bid for 28 days
in this study was associated with a substantial rise in plasma
adiponectin. The magnitude of the change was similar to
that which has previously observed in patients with type II
diabetes during treatment with rosiglitazone.20 The dose of
rosiglitazone was selected on the basis that, of the regi-
mens tested, this was associated with the greatest effect
on plasma glucose in patients with type II diabetes,21 andhas a safety profile appropriate for investigative adminis-
tration to patients with mild asthma.
Treatment with rosiglitazone was not associated with
any effect on the EAR. The EAR is mediated by acute
inflammatory mediators such as prostaglandins and leuko-
trienes; rosiglitazone was not expected to have an effect
on this response. By contrast, treatment with rosigliata-
zone was associated with a statically significant reduction
in the weighted mean LAR compared with placebo. The
magnitude of the effect was however modest (15%). Clini-
cally effective anti-inflammatories such as corticosteroids
are associated with an approximately 90% attenuation of
the LAR.22,23 Montelukast, a leukotriene antagonist widely
used in asthma but considered to have limited anti-
inflammatory effects, has its principal effect on the EAR,
but is also associated with approximately 25% attenuation
of LAR.23,24 In this context, the 15% attenuation associated
with rosiglitazone is unlikely to be associated with
a substantial impact during treatment of clinical asthma.
The methacholine response on day 29 supported this
conclusion: rosiglitazone required a lower concentration of
methacholine to achieve at least a 20% fall in FEV1 when
compared with placebo, but this did not reach statistical or
clinical significance. The dataset for the stand alone AMP
challenge on day 14 is limited but is consistent with the
response observed for the methacholine challenge.
Exhaled NO is widely used as a measure of airway
inflammation.25,26 Consistent with the LAR findings, treat-
ment with rosiglitazone in this population of mild asth-
matics was associated with a (pre-dose) reduction in FENO
that was statistically greater than that observed during
treatment with placebo. The blood biomarker data only
show substantial effects on adiponectin, a marker of PPAR
activation. Trends towards a reduction in inflammatory
markers were observed (e.g. IL-4, IL-6, IL-13), but none of
these were considered major effects. There were no trends
observed in the blood differential white cell count.
Like all models, the allergen challenge has its limita-
tions, but it is a sensitive measure of the potential for
clinically effective anti-inflammatory drugs. All drugs that
have clinically useful anti-inflammatory actions have
a beneficial effect on the LAR.27 In view of the modest
effect on the allergen challenge the ability of the
biomarker data to inform on the mechanism of the
observed effect is limited. The observed reduction in FENO
is consistent with in vitro observations that PPARg agonist
activity is associated with an inhibition of NO synthase.
Although statistically significant the magnitude of the
reduction is smaller than observed with inhaled cortico-
steroids (e.g. fluticasone).28 The findings of this study are
Treatment with a PPARg agonist in asthma 673consistent with in vitro studies but the concentrations
associated with effects on nitric oxide synthase in vitro are
observed at high concentrations (10 mM) and there is some
evidence that these actions may be PPARg independent.29
This raises the possibility that much higher doses of a PPARg
agonist may be required to achieve all the anti-inflamma-
tory effects observed in vitro; this is however somewhat
speculative given the good evidence for substantial PPARg
activation seen in this study. In addition PPARg agonists are
associated with dose-related adverse effects such as weight
gain (probably secondary to fluid retention), therefore
substantially higher doses may not associated with a posi-
tive benefit/risk profile in asthma.
It is of note that Spears et al observed a clinically rele-
vant improvement in FEV1 in smoking asthmatics treated
with rosiglitazone for 4 weeks. The population in that study
is markedly more severe than that studied here (FEV 70e
75% predicted vs 89% in this study; clinical requirement for
inhaled corticosteroids).5 Smoking asthmatics show corti-
costeroid insensitivity. The mechanisms underlying this are
not fully characterized but have been postulated to involve
a change in cytokine profile resulting in altered glucocor-
ticoid receptor signalling, a reduction in the activity of
HDAC, and an increase in competing molecular events.30
Which of these may be responsible for the differences
observed is not known.
Conclusion
Treatment with a PPARg agonist (rosiglitazone) was asso-
ciated with a modest (15%) reduction in the late asthmatic
reaction in the allergen challenge model of asthma. This
was accompanied by trends in other markers of efficacy and
anti-inflammatory activity but none were considered major
effects. In conclusion the findings of this study would imply
that a PPARg agonist alone is unlikely to be a clinically
effective anti-inflammatory in mild asthma when used
alone. The intriguing differences between the results of
this study and another in smoking asthmatics would benefit
from further mechanistic evaluation.
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